Form 4: Adicet Bio Director Lloyd Klickstein Granted Equity Compensation

Adicet Bio, Inc. Director Lloyd Klickstein was granted 5,900 Restricted Stock Units and options to purchase 26,400 shares of common stock as part of his compensation.

Summary

• Director Lloyd Klickstein of Adicet Bio, Inc. was granted equity awards on June 11, 2025.
• He received 5,900 Restricted Stock Units (RSUs) at a grant price of $0, representing a contingent right to receive one share of Common Stock per RSU.
• He also received stock options to purchase 26,400 shares of common stock at an exercise price of $0.78 per share, with an expiration date of June 10, 2035.
• Both the RSUs and stock options are subject to vesting, which will occur in full on the earlier of (i) the first anniversary of the grant date (June 11, 2026) or (ii) the date of the next annual meeting of stockholders following the grant date.
• Vesting is contingent upon Mr. Klickstein's continued service on the Issuer's board of directors.
• Following these transactions, Mr. Klickstein beneficially owns 108,566 shares of common stock and 26,400 stock options.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning interests but not a significant market-moving event on its own.

Positives

• The grant of equity awards, including Restricted Stock Units and stock options, aligns the director's financial interests with those of the company's shareholders, encouraging long-term value creation.
• This compensation package serves to retain and incentivize the director for his continued service on the board of Adicet Bio, Inc.

Future Outlook

The vesting schedule for the granted RSUs and stock options implies an expectation of Director Lloyd Klickstein's continued service on the Adicet Bio board until at least the first anniversary of the grant date or the next annual meeting of stockholders.

Industry Context

This Form 4 filing details a routine insider transaction, specifically the grant of equity compensation to a director. Such grants are a standard practice across publicly traded companies in various industries to align the interests of board members and executives with those of shareholders. This filing does not provide specific insights into broader industry trends or competitive landscapes.

Related Party Transactions

• The grant of Restricted Stock Units and stock options to Director Lloyd Klickstein constitutes a related party transaction, as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially fostering long-term value creation. However, the future issuance of shares upon vesting and exercise will result in minor dilution.
• Director (Lloyd Klickstein): Receives equity compensation, increasing his beneficial ownership in the company and tying a portion of his future compensation directly to the company's stock performance.

Next Steps

• Vesting of 5,900 Restricted Stock Units on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders, subject to continued service.
• Vesting of 26,400 stock options on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders, subject to continued service.

Key Dates

Keywords

Adicet Bio, ACET, Form 4, SEC filing, insider transaction, Restricted Stock Units, RSUs, stock options, equity compensation, director compensation, beneficial ownership